Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    185
    ...
ATC Name B/G Ingredients Dosage Form Price
A04AA01 ONDEMED G Ondansetron (HCl) - 4mg/5ml 4mg/5ml Solution 858,779 L.L
A10BD07 ZERILUX G Sitagliptin - 25mg/ml 25mg/ml Solution 1,172,179 L.L
B01AC04 NORMIGORE G Clopidogrel (Bisulfate) - 75mg 75mg Tablet, film coated 1,184,117 L.L
B05BB02 SERUFLEX DEXTROSE 5% SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9%, Glucose - 5% Injectable solution 194,211 L.L
B05ZA CONCENTRATE SOLUTION FOR HEMODIALYSIS TYPE J G Hemodialytics, concentrates - Injectable solution L.L
C08CA01 LUSTRA G Amlodipine - 5mg 5mg Tablet 485,127 L.L
C09DB07 CORONOPINE G Candesartan cilexetil - 8mg, Amlodipine - 10mg Capsule, hard 1,368,032 L.L
D04AB01 PROCOMIL G Lidocaine - 10% 10% Spray 139,760 L.L
G03AD01 EZ-ONE G Levonorgestrel - 1.5mg 1.5mg Tablet 722,987 L.L
H02AB07 PREDICOR G Prednisone - 5mg 5mg Tablet, scored 174,060 L.L
J01DD08 MAGNACEF 400 G Cefixime - 400mg 400mg Capsule 1,232,304 L.L
J02AC01 STABILANOL G Fluconazole - 100mg 100mg Capsule 1,432,331 L.L
L01BC02 5-FROTU G Fluorouracil - 1000mg/20ml 1000mg/20ml Injectable solution 577,852 L.L
M01AH05 ETOXIB G Etoricoxib - 60mg 60mg Tablet, film coated 694,767 L.L
N04BA03 COMBIPAR G Levodopa - 100mg, Carbidopa - 25mg, Entacapone - 200mg Tablet, film coated 1,249,926 L.L
N06AB10 ESCITALOPRAM BIOGARAN G Escitalopram (oxalate) - 20mg 20mg Tablet, coated, scored 678,640 L.L
R03AC13 AEROFOR G Formoterol fumarate - 12mcg 12mcg Capsule, inhalation 897,687 L.L
R06AX27 AERIALLERG G Desloratadine - 5mg 5mg Tablet, film coated 400,465 L.L
A04AA01 ONZO G Ondansetron (HCl dihydrate) - 4mg/5ml 4mg/5ml Solution 1,283,370 L.L
B01AC04 PEDOVEX G Clopidogrel (Bisulfate) - 75mg 75mg Tablet, film coated 808,993 L.L
B05BB02 SERUFLEX DEXTROSE 5% SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9%, Glucose - 5% Injectable solution 180,421 L.L
C08CA01 NIPIDOL G Amlodipine - 5mg 5mg Tablet 255,330 L.L
C09DX LOSANET AM PLUS G Losartan potassium - 100mg, Amlodipine - 10mg, Hydrochlorothiazide - 12.5mg Tablet 1,044,358 L.L
G03AD01 PURPLE LINE G Levonorgestrel - 1.5mg 1.5mg Tablet, film coated 1,071,570 L.L
H02AB07 PREDNISONE G Prednisone - 5mg 5mg Tablet, scored 176,619 L.L
J01DD08 MUREX G Cefixime - 400mg 400mg Capsule 679,984 L.L
N04BA03 COMBIPAR G Levodopa - 150mg, Carbidopa - 37.5mg, Entacapone - 200mg Tablet, film coated 1,324,682 L.L
N06AB10 PRAMACYT 20 G Escitalopram (oxalate) - 20mg 20mg Tablet, film coated 972,686 L.L
R03AC13 AEROFOR G Formoterol fumarate - 12mcg 12mcg Capsule, inhalation 1,709,368 L.L
R06AX27 DAREQ G Desloratadine - 5mg 5mg Tablet, film coated 258,018 L.L
    ...
    185
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026